Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BUSPIRONE HYDROCHLORIDE

8 general benefit · 1 not a benefit

Other products in the same Health Canada class (N05B) — coverage varies; not interchangeable

  • Lorazepam (Ativan): limited Use 481, Not a benefit

AMB-Buspirone · DIN 02550555 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
AMB-Buspirone · DIN 02550555 Manufacturer: Ambicare Pharmaceuticals Inc.; listing date 2025-04-30 Health Canada: Marketed since 2024-09-24 · brand AMB-BUSPIRONE · ATC N05BE01 BUSPIRONE · form Tablet · route Oral · ingredients BUSPIRONE HYDROCHLORIDE 10 MG · company Ambicare pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

AMB-Buspirone: Formulary list price $0.2713/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2713 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103936 · Verify on the e-Formulary ↗ (DIN 02550555)

Source record
DIN 02550555: AMB-Buspirone Raw flags: sec3=Y Item: 282400166; group id 519; item number 1406; lccId None; manufacturer id AMB Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.2713; ministry $0.2713 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02550555 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103936
Interchangeable products
Apo-Buspirone · DIN 02211076 · $0.2713 Auro-Buspirone · DIN 02500213 · $0.2713 Buspar · DIN 00603821 · not recorded Buspirone · DIN 02447851 · $0.2713 Jamp Buspirone · DIN 02509911 · $0.2713 Mint-Buspirone · DIN 02519054 · $0.2713 PMS-Buspirone · DIN 02230942 · $0.2713 Teva-Buspirone · DIN 02231492 · $0.2713
Shortage status: resolved shortage (ended 2026-06-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02550555
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Buspirone · DIN 02500213 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Buspirone · DIN 02500213 Manufacturer: Auro Pharma Inc.; listing date 2021-02-26 Health Canada: Marketed since 2020-10-30 · brand AURO-BUSPIRONE · ATC N05BE01 BUSPIRONE · form Tablet · route Oral · ingredients BUSPIRONE HYDROCHLORIDE 10 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Buspirone: Formulary list price $0.2713/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2713 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98992 · Verify on the e-Formulary ↗ (DIN 02500213)

Source record
DIN 02500213: Auro-Buspirone Raw flags: sec3=Y Item: 282400166; group id 519; item number 1406; lccId None; manufacturer id AUR Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.2713; ministry $0.2713 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02500213 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98992
Interchangeable products
AMB-Buspirone · DIN 02550555 · $0.2713 Apo-Buspirone · DIN 02211076 · $0.2713 Buspar · DIN 00603821 · not recorded Buspirone · DIN 02447851 · $0.2713 Jamp Buspirone · DIN 02509911 · $0.2713 Mint-Buspirone · DIN 02519054 · $0.2713 PMS-Buspirone · DIN 02230942 · $0.2713 Teva-Buspirone · DIN 02231492 · $0.2713
Shortage status: resolved shortage (ended 2026-08-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02500213
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Buspirone · DIN 02509911 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Buspirone · DIN 02509911 Manufacturer: Jamp Pharma Corporation; listing date 2021-12-17 Health Canada: Marketed since 2021-10-29 · brand JAMP BUSPIRONE · ATC N05BE01 BUSPIRONE · form Tablet · route Oral · ingredients BUSPIRONE HYDROCHLORIDE 10 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Buspirone: Formulary list price $0.2713/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2713 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99918 · Verify on the e-Formulary ↗ (DIN 02509911)

Source record
DIN 02509911: Jamp Buspirone Raw flags: sec3=Y Item: 282400166; group id 519; item number 1406; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.2713; ministry $0.2713 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02509911 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99918
Interchangeable products
AMB-Buspirone · DIN 02550555 · $0.2713 Apo-Buspirone · DIN 02211076 · $0.2713 Auro-Buspirone · DIN 02500213 · $0.2713 Buspar · DIN 00603821 · not recorded Buspirone · DIN 02447851 · $0.2713 Mint-Buspirone · DIN 02519054 · $0.2713 PMS-Buspirone · DIN 02230942 · $0.2713 Teva-Buspirone · DIN 02231492 · $0.2713
Shortage status: resolved shortage (ended 2025-01-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02509911
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Buspirone · DIN 02519054 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Buspirone · DIN 02519054 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-01-26 · brand MINT-BUSPIRONE · ATC N05BE01 BUSPIRONE · form Tablet · route Oral · ingredients BUSPIRONE HYDROCHLORIDE 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Buspirone: Formulary list price $0.2713/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2713 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100833 · Verify on the e-Formulary ↗ (DIN 02519054)

Source record
DIN 02519054: Mint-Buspirone Raw flags: sec3=Y Item: 282400166; group id 519; item number 1406; lccId None; manufacturer id MIN Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.2713; ministry $0.2713 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519054 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100833
Interchangeable products
AMB-Buspirone · DIN 02550555 · $0.2713 Apo-Buspirone · DIN 02211076 · $0.2713 Auro-Buspirone · DIN 02500213 · $0.2713 Buspar · DIN 00603821 · not recorded Buspirone · DIN 02447851 · $0.2713 Jamp Buspirone · DIN 02509911 · $0.2713 PMS-Buspirone · DIN 02230942 · $0.2713 Teva-Buspirone · DIN 02231492 · $0.2713
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519054
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Buspirone · DIN 02230942 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Buspirone · DIN 02230942 Manufacturer: Pharmascience Inc.; listing date 2007-11-16 Health Canada: Marketed since 1997-05-26 · brand PMS-BUSPIRONE · ATC N05BE01 BUSPIRONE · form Tablet · route Oral · ingredients BUSPIRONE HYDROCHLORIDE 10 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Buspirone: Formulary list price $0.2713/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2713 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50220 · Verify on the e-Formulary ↗ (DIN 02230942)

Source record
DIN 02230942: PMS-Buspirone Raw flags: sec3=Y Item: 282400166; group id 519; item number 1406; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.2713; ministry $0.2713 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230942 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50220
Interchangeable products
AMB-Buspirone · DIN 02550555 · $0.2713 Apo-Buspirone · DIN 02211076 · $0.2713 Auro-Buspirone · DIN 02500213 · $0.2713 Buspar · DIN 00603821 · not recorded Buspirone · DIN 02447851 · $0.2713 Jamp Buspirone · DIN 02509911 · $0.2713 Mint-Buspirone · DIN 02519054 · $0.2713 Teva-Buspirone · DIN 02231492 · $0.2713
Shortage status: resolved shortage (ended 2026-08-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230942
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Buspirone · DIN 02231492 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Buspirone · DIN 02231492 Manufacturer: Teva Canada Limited; listing date 2007-11-10 Health Canada: Marketed since 2015-06-04 · brand TEVA-BUSPIRONE · ATC N05BE01 BUSPIRONE · form Tablet · route Oral · ingredients BUSPIRONE HYDROCHLORIDE 10 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Buspirone: Formulary list price $0.2713/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2713 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50822 · Verify on the e-Formulary ↗ (DIN 02231492)

Source record
DIN 02231492: Teva-Buspirone Raw flags: sec3=Y Item: 282400166; group id 519; item number 1406; lccId None; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.2713; ministry $0.2713 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231492 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50822
Interchangeable products
AMB-Buspirone · DIN 02550555 · $0.2713 Apo-Buspirone · DIN 02211076 · $0.2713 Auro-Buspirone · DIN 02500213 · $0.2713 Buspar · DIN 00603821 · not recorded Buspirone · DIN 02447851 · $0.2713 Jamp Buspirone · DIN 02509911 · $0.2713 Mint-Buspirone · DIN 02519054 · $0.2713 PMS-Buspirone · DIN 02230942 · $0.2713
Shortage status: discontinued (2026-05-05, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231492
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Buspirone · DIN 02211076 · 10mg · tablet

General benefitDormant since 2025-10-02 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Buspirone · DIN 02211076 Manufacturer: Apotex Inc.; listing date 2007-11-16 Health Canada: Dormant since 2025-10-02 · brand APO-BUSPIRONE · ATC N05BE01 BUSPIRONE · form Tablet · route Oral · ingredients BUSPIRONE HYDROCHLORIDE 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Buspirone: Formulary list price $0.2713/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2713 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20011 · Verify on the e-Formulary ↗ (DIN 02211076)

Source record
DIN 02211076: Apo-Buspirone Raw flags: sec3=Y Item: 282400166; group id 519; item number 1406; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.2713; ministry $0.2713 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02211076 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20011
Interchangeable products
AMB-Buspirone · DIN 02550555 · $0.2713 Auro-Buspirone · DIN 02500213 · $0.2713 Buspar · DIN 00603821 · not recorded Buspirone · DIN 02447851 · $0.2713 Jamp Buspirone · DIN 02509911 · $0.2713 Mint-Buspirone · DIN 02519054 · $0.2713 PMS-Buspirone · DIN 02230942 · $0.2713 Teva-Buspirone · DIN 02231492 · $0.2713
Shortage status: active shortage (reported 2024-01-23, last updated 2024-02-02) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02211076
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-10-02 — choose a marketed DIN from the same-category list.

Buspirone · DIN 02447851 · 10mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-01-12 — choose a marketed DIN from the same-category list.Discontinued 2026-01-12 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-01-12 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-01-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Buspirone · DIN 02447851 Manufacturer: Sanis Health Inc.; listing date 2016-07-28 Health Canada: Cancelled post market since 2026-01-12 · brand BUSPIRONE · ATC N05BE01 BUSPIRONE · form Tablet · route Oral · ingredients BUSPIRONE HYDROCHLORIDE 10 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Buspirone: Formulary list price $0.2713/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2713 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93348 · Verify on the e-Formulary ↗ (DIN 02447851)

Source record
DIN 02447851: Buspirone Raw flags: sec3=Y Item: 282400166; group id 519; item number 1406; lccId None; manufacturer id SAI Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.2713; ministry $0.2713 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02447851 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93348
Interchangeable products
AMB-Buspirone · DIN 02550555 · $0.2713 Apo-Buspirone · DIN 02211076 · $0.2713 Auro-Buspirone · DIN 02500213 · $0.2713 Buspar · DIN 00603821 · not recorded Jamp Buspirone · DIN 02509911 · $0.2713 Mint-Buspirone · DIN 02519054 · $0.2713 PMS-Buspirone · DIN 02230942 · $0.2713 Teva-Buspirone · DIN 02231492 · $0.2713
Shortage status: active shortage (reported 2025-12-17, last updated 2026-06-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02447851
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-01-12 — choose a marketed DIN from the same-category list.

Buspar · DIN 00603821 · 10mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-11-12 — choose a marketed DIN from the same-category list.Discontinued 2010-11-12 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-11-12 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2010-11-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Buspar · DIN 00603821 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2007-11-10 Health Canada: Cancelled post market since 2010-11-12 · brand BUSPAR TAB 10MG · ATC N05BE01 BUSPIRONE · form Tablet · route Oral · ingredients BUSPIRONE HYDROCHLORIDE 10 MG · company Bristol-myers squibb canada · schedule Prescription
Check this DIN again · Health Canada product record

Buspar: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10204 · Verify on the e-Formulary ↗ (DIN 00603821)

Source record
DIN 00603821: Buspar Raw flags: notABenefit=Y, sec3=Y Item: 282400166; group id 519; item number 1406; lccId None; manufacturer id BQU Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00603821 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10204
Interchangeable products
AMB-Buspirone · DIN 02550555 · $0.2713 Apo-Buspirone · DIN 02211076 · $0.2713 Auro-Buspirone · DIN 02500213 · $0.2713 Buspirone · DIN 02447851 · $0.2713 Jamp Buspirone · DIN 02509911 · $0.2713 Mint-Buspirone · DIN 02519054 · $0.2713 PMS-Buspirone · DIN 02230942 · $0.2713 Teva-Buspirone · DIN 02231492 · $0.2713
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00603821
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2010-11-12 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered

Matched class: 28:24 Sedatives and Hypnotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM Some products covered without a code (check the product listing): FLURAZEPAM, METHOTRIMEPRAZINE, TRIAZOLAM 28:24 Sedatives and Hypnotics

LORAZEPAM

· 9 products · Listed, not a benefit (1), Limited Use, codes 481 (2), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 4mg/mL, 0.5mg, 1mg, 2mg · Inj Sol (with preservative), SL Tab

FLURAZEPAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 15mg, 30mg · Cap

METHOTRIMEPRAZINE

· 9 products · General benefit (5), Listed, not a benefit (4) · strengths: 25mg/mL, 2mg, 5mg, 25mg, 50mg · Inj Sol-1mL Pk, Tab

NITRAZEPAM

· 2 products · General benefit · strengths: 5mg, 10mg · Tab

PHENOBARBITAL

· 5 products · General benefit · strengths: 5mg/mL, 15mg, 30mg, 60mg, 100mg · Oral Elixir, Tab

TEMAZEPAM

· 2 products · General benefit · strengths: 15mg, 30mg · Cap

TRIAZOLAM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.125mg, 0.25mg · Tab

MIDAZOLAM

· 3 products · Listed, not a benefit (1), Limited Use, codes 495, 496 (2) · strengths: 5mg/mL · Inj Sol (with Preservative)

ESZOPICLONE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 3mg · Tab

ZOLPIDEM TARTRATE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · SL Tab

ZOPICLONE

· 40 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3.75mg, 5mg, 7.5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:24
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS pms-BUSPIRONE (buspirone hydrochloride) is indicated for: • short term symptomatic relief of excessive anxiety in patients with Generalized Anxiety Disorder The effectiveness of buspirone hydrochloride in long-term use (i.e. more than 4 weeks) has not been evaluated in controlled clinical trials. 1.1 Pediatrics Pediatrics (˂ 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: Buspirone has not been systematically evaluated in geriatric patients. Although it would appear from limited pharmacokinetic and clinical studies that buspirone does not behave differently in the elderly, there is little known about the effects of buspirone in this age group at doses above 30 mg/day (See 7.1.4 Geriatrics). Long-term use of pms-BUSPIRONE should be avoided in geriatric patients. Enhanced monitoring is recommended (see 7 WARNINGS AND PRECAUTIONS, Falls and Fractures; 4 .DOSAGE AND ADMINISTRATION, Dosing Considerations). https://pdf.hres.ca/dpd_pm/00072520.PDF PM date: MAR 18, 1997 Source product: PMS-BUSPIRONE; DIN 02230942; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Buspirone · DIN 02231492 Shortage status: discontinued (2026-05-05, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231492

Check this DIN again

Apo-Buspirone · DIN 02211076 Shortage status: active shortage (reported 2024-01-23, last updated 2024-02-02) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02211076

Check this DIN again

Buspirone · DIN 02447851 Shortage status: active shortage (reported 2025-12-17, last updated 2026-06-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02447851

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Buspar: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026